ALX Oncology (NASDAQ:ALXO – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.01, FiscalAI reports.
ALX Oncology Stock Performance
NASDAQ:ALXO opened at $1.04 on Monday. ALX Oncology has a twelve month low of $0.86 and a twelve month high of $2.66. The company has a quick ratio of 9.71, a current ratio of 9.71 and a debt-to-equity ratio of 0.07. The business has a 50 day moving average price of $1.35 and a two-hundred day moving average price of $1.81. The company has a market cap of $143.81 million, a P/E ratio of -0.92 and a beta of 0.61.
Analyst Ratings Changes
Several equities research analysts have recently issued reports on the stock. Weiss Ratings raised shares of ALX Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 17th. Wall Street Zen lowered shares of ALX Oncology from a “hold” rating to a “sell” rating in a report on Saturday. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $4.75.
Check Out Our Latest Analysis on ALX Oncology
ALX Oncology Company Profile
ALX Oncology Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer. Its research centers on the CD47 immune checkpoint, a signal that can help cancer cells evade the immune system. The company’s lead candidate, evorpacept (also known as ALX148), is an investigational CD47-blocking protein designed to support the immune system’s ability to recognize and attack cancer cells. ALX Oncology has studied evorpacept in combination with other cancer treatments across several tumor types.
Read More
- Five stocks we like better than ALX Oncology
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
Receive News & Ratings for ALX Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALX Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
